VivoSeq
Immunology

Allergic Asthma

55

Pipeline Programs

5

Active Trials

24

Companies Involved

Allergic Asthma is a moderately active landscape with 55 programs across 24 companies. The most active players are Jasper Therapeutics, Inc., Zhejiang Kanova Biopharmaceutical Co., LTD, OM Pharma SA. 6 therapies are approved with 9 more in late-stage development.

Pipeline Metrics

Competitive Density

61/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

80/100

Attrition Rate

18/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

84%

Small molecule

46 of 55 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody713%Peptide24%

Small molecule leads; the ring shows all 55 classified programs, each share of the total. Modality classified for 99% of 67 pipeline programs.

Trial Status

67

clinical trials

Completed47 · 70%
Terminated8 · 12%
Withdrawn4 · 6%
Unknown status3 · 4%
Recruiting3 · 4%
Active, not recruiting1 · 1%
Other1 · 1%

Trial Activity

67 trials

Trial of JYB1904 in Patients With Allergic Asthma
Active, not recruiting·JJemincare·Phase 2·NCT06438757·69 enrolled
Biomarkers of Irritant-Induced and Allergic Asthma
Completed·NNYU Langone Health·Phase 2·NCT02740543·18 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)